Liminatus Pharma, Inc.
LIMN
$0.14
$0.013.85%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 319.02% | 360.34% | 329.03% | 127.02% | -0.72% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 101.98% | -10.87% | -42.65% | -53.72% | -58.83% |
| Operating Income | -101.98% | 10.87% | 42.65% | 53.72% | 58.83% |
| Income Before Tax | -419.02% | -187.80% | 44.53% | 77.65% | 55.15% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -419.02% | -187.80% | 44.53% | 77.65% | 55.15% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -419.02% | -187.80% | 44.53% | 77.65% | 55.15% |
| EBIT | -101.98% | 10.87% | 42.65% | 53.72% | 58.83% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -226.34% | -88.89% | 51.93% | 64.48% | 4.42% |
| Normalized Basic EPS | -74.37% | 1.90% | 11.00% | 29.96% | 4.30% |
| EPS Diluted | -226.34% | -88.89% | 51.93% | 64.48% | 4.42% |
| Normalized Diluted EPS | -74.37% | 1.90% | 11.00% | 29.96% | 4.30% |
| Average Basic Shares Outstanding | 62.01% | 35.59% | -48.24% | -70.82% | -80.25% |
| Average Diluted Shares Outstanding | 62.01% | 35.59% | -48.24% | -70.82% | -80.25% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |